BioPharm International’s Partnerships for Outsourcing eBook
Read the article:
The Essential Ingredient in any Sponsor-CRO Partnership: Trust
Read the eBook:
The Essential Ingredient in any Sponsor-CRO Partnership: Trust
By Peter Gaskin
Publication
Article
BioPharm InternationalBioPharm International, Partnerships for Outsourcing May 2022
Volume 2022 eBook
Issue 2
Pages: 8–13
To build trust and ensure a high-quality product, companies must be sure their contracts are firm and their lines of communication even firmer.
AdobeStock_289149774_lidiia
It wasn’t long ago that pharmaceutical companies did their own research and development in-house, from discovery through investigational new drug (IND) submission. Today, it’s hard to find pharmaceutical companies of any size, from large global pharmaceutical entities down to the smallest biotech company, that has not outsourced some aspects of their work to a third-party organization, whether that be academic institutions, biotech startups, or contract research organizations (CROs). These relationships are likely to continue to grow exponentially. A new market report released this year estimates that the global biotechnology and pharmaceutical services outsourcing market will surpass $91.4 billion US by 2028 because of a 5.2% compound annual growth rate (CAGR) (1).
Today, roughly two-thirds of R&D is being outsourced, with CROs growing dramatically to fill the gap. How can service providers and clients assure that the relationship will be mutually advantageous? What are some of the best practices to ensure a high-quality product? This article will look at how to ensure contracts are established and signed quickly so that science moves forward, why quality assurance (QA) is integral to meeting regulatory compliance, how compromise and coordination are necessary for any winning partnership, and whether geography is important given the globalization of today’s economy.
Read this article in BioPharm International’s Partnerships for Outsourcing eBook.
Reference
1. H. Balfour, “Biotech and Pharma Services Outsourcing Market to Be Worth Over $91bn by 2028,” EuropeanPharmaceuticalReview.com, April 13, 2021.
About the author
Peter Gaskin, PhD, is the senior director of scientific advisory services for Charles River, an AAPS sustaining partner.
Article details
BioPharm International
eBook: Partnerships for Outsourcing
May 2022
Pages: 8–13
Citation
When referring to this article, please cite it as P. Gaskin, "The Essential Ingredient in any Sponsor-CRO Partnership: Trust," BioPharm International’s Partnerships for Outsourcing eBook (May 2022).
Articles in this issue
Balancing Internal Focus Against External Capabilities
The Essential Ingredient in any Sponsor-CRO Partnership: Trust
Fostering Orphan Drugs
Preparing for the Future: Expanding Capacity and Facilitating Multi-modalities
The CDMO Carousel
What Outsourcing Partners Wish You Knew
Converting Injectable Therapies to Combination Drug-Device Products
Recent Videos
Related Content
